Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays dropped their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Down 8.1 %

CLLS stock opened at $1.93 on Wednesday. The firm has a market capitalization of $107.28 million, a PE ratio of -1.48 and a beta of 3.08. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38. The stock’s 50 day moving average is $1.85 and its 200-day moving average is $2.01.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the business posted ($0.31) earnings per share. Sell-side analysts expect that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Cellectis in the second quarter worth about $29,000. First Affirmative Financial Network bought a new stake in shares of Cellectis in the 3rd quarter worth approximately $45,000. Principal Financial Group Inc. lifted its stake in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC grew its holdings in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.